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Objective:  Study  of  the  association  between  immunoglobulin-G  (IgG)  subclass  deﬁciency  and  nasal  poly-
posis.
Material  and  methods:  Longitudinal  study  (5 years)  in  a prospective  cohort  of 161 nasal  polyposis  patients.
Analysis  of  the  association  between  humoral  immunodeﬁciency,  rhinologic  symptoms,  endoscopy  score
and prescribed  doses  of  local  and  systemic  corticosteroids.
Results:  The  prevalence  of  IgG  subclass  deﬁciency  was  13.7%  (22/161).  One  patient  was  diagnosed
with  common  variable  immunodeﬁciency  (CVID).  No  signiﬁcant  differences  were  observed  between  the
groups with  and  without  pre-treatment  deﬁciency  for symptom  severity,  endoscopic  score  or  local  or
systemic  corticosteroid  regimens  at baseline  or  during  the  5  years,  following  initiation  of  medical  and  sur-
gical  treatment.  Only  the  Lund–Mackay  CT score  was  signiﬁcantly  higher  in  the  pre-treatment  deﬁciency
group.
Conclusion:  There  was  no  correlation  between  the  presence  of humoral  deﬁciency  and  either  symptom
evolution  after medical  and  surgical  treatment  or the dose  of  corticosteroids  needed  to  control  disease.
Thus,  a  link  between  IgG  subclass  deﬁciency  and  nasal  polyposis  seems  unlikely.. Introduction
Nasal polyposis is a form of diffuse chronic rhinosinusitis char-
cterized by the bilateral presence of multifocal sinus polyps. The
istologic aspect is of chronic inﬂammation, but physiopathol-
gy remains unknown: several hypotheses have been put forward,
mplicating immune reaction to bacterial, fungal or allergic factors
1–3].
Oxelius [4] in 1974, ﬁrst described hereditary IgG2 and IgG4 deﬁ-
iency associated with speciﬁc polysaccharide antigen antibody
eﬁciency in a mother and her two children who  suffered iterative
. Inﬂuenzae infection causing recurrent otitis and bronchop-
eumonia. The symptoms of immunoglobulin-G (IgG) subclass
eﬁciency mainly consist of infection involving the upper air-
ays, allergic and autoimmune forms have also been reported. As
he evolution of polyposis features recurrent episodes of bacterial
uperinfection, humoral immunodeﬁciency may  be suspected in
evere forms of nasal polyposis. The only study presently published,
owever, focused on the prevalence of humoral immunodeﬁ-
iency in refractory rhinosinusitis and reported varying results:
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immunodeﬁciency was  detected in a range as wide as 5–63%
of cases, with considerable variation in the incidence of speciﬁc
deﬁciencies, such as IgA deﬁciency, common variable immune deﬁ-
ciency (CVID) and IgG subclass deﬁciency [5,6].
There have been no speciﬁc studies of the association between
IgG subclass deﬁciency and nasal polyposis. The principal objective
of the present study was therefore to determine the prevalence
and any correlation between IgG subclass deﬁciency and polyposis
severity.
2. Material and methods
A prospective study enrolled 118 patients operated on for
nasal polyposis between 2005 and 2010 and 43 nasal polyposis
patients who  had not undergone surgery and consulted for the ﬁrst
time between 2010 and 2011. Mean age was 46 years (median,
47 years; range, 15–81 years). All patients were examined, oper-
ated on and followed up by a single surgeon. Nasal polyposis was
diagnosed from an aspect of bilateral nasal cavity polyps and bilat-
eral panethmoidal opaciﬁcation on sinus CT scan. Cases of nasal
polyposis associated with cystic ﬁbrosis, primary ciliary dyskine-
sia, Wegener’s granulomatosis or Churg–Strauss syndrome were
excluded from analysis.
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Table 1
General sample characteristics.
Without immune
deﬁciency (n = 138)
With immune
deﬁciency (n = 23)
P
Age (years) 46.3 (15–81) 47.3 (25–67)
Follow-up (months) 52.7 (0–240) 66.6 (2–21640)
Sex ratio 1.82 1.30
History of surgery 38 89 0.376
Allergy 44 43 0.111
Asthma 60 15 0.087
Bronchial hyperreactivity 96 16 0.807
Aspirin intolerance 27 8 0.172
Widal triad 22 7 0.167
Table 2
Type of humoral immunodeﬁciency.
Type of deﬁciency Medical treatment Surgical treatment
IgG1 3 8
IgG1 + IgG3 0 4
IgG2 1 0
IgG3 0 6
The most frequent symptoms at inclusion were anosmia, nasal
obstruction and posterior rhinorrhea. Prevalence was comparable
in the 2 groups (with and without Ig subclass deﬁciency) (Table 3).
Allowing for the fact that quality of life is impaired by symptom
Table 3
Comparison of number of patients with and without humoral immunodeﬁciency
presenting rhinologic symptoms at ﬁrst consultation.
NO AR PR Snz FP OD
Without deﬁciency 123 101 106 56 59 12972 N. Tran Khai Hoan et al. / European Annals of Otorhin
Immunologic exploration comprised immunoglobulin quanti-
ation and IgG subclass assay. Initial assays were performed in a
ommunity setting: immunoglobulin quantitation by turbidime-
ry and IgG subclass assay by nephelometry (Cerba Laboratory
nd Biomnis Laboratory). When deﬁciency was detected, a sec-
nd assay was performed in the immunology laboratory of the
ecker Hospital for Sick Children: immunoglobulin quantitation
y immunonephelometry and IgG subclass assay by immuno-
nzymatic analysis using monoclonal antibodies. In case of proven
iological deﬁciency, the clinical impact of the IgG subclass deﬁ-
iency was assessed on biological analysis and in immunologic
onsultation in terms of recurrent infection; replacement therapy
as discussed.
.1. Data
The severity of nasal polyposis was assessed at 6 months’ and 1,
, 3, 5 and 7 years’ follow-up in patients having undergone surgery.
ean follow-up for patients managed surgically was  71 months
median, 60 months) and 23 months for patients managed medi-
ally. Clinical status was assessed at each consultation on 6 criteria:
asal obstruction (NO), anterior rhinorrhea (AR), posterior rhinor-
hea (PR), dysosmia (Do), sneezing (Snz) and facial pain (FP). Each
as assessed on a 3-point scale [7]:
0 = no symptoms;
1 = moderate symptom without impact on daily life;
2 = severe symptom impairing normal everyday activity.
In the case of dysosmia, 2 represented anosmia, 1 hyposmia and
 normal olfaction. A global clinical score was computed by aver-
ging the 6 symptom scores. Fiberoptic endoscopy, performed at
ach consultation, graded polyps as follows:
0 = no polyps;
1 = small polyps reaching the inferior edge of the middle nasal
concha;
2 = medium-sized polyps between the inferior edge of the middle
nasal concha and the inferior edge of the inferior nasal concha;
3 = severe polyps extending beyond the inferior edge of the infe-
rior nasal concha [7].
CT assessment of polyposis before treatment used the
und–Mackay score [7]. Two complementary explorations were
erformed: the Phadiatop® test, and methacholine pulmonary
unction test. The prevalence of allergy was 29.1%, of asthma 46.6%,
f aspirin intolerance 21.7%, and of Widal triad 18.0%. There were
o cases of other immune disorders (Hashimoto, Biermer, etc.).
.2. Treatment
All patients received twice-daily cleansing of the nasal cavities,
ocal corticotherapy (equivalent to beclomethasone, 400 g/day)
nd short-course oral corticosteroids (1 mg/kg/day for 6 days). Oral
orticotherapy was prescribed when symptoms became disabling,
hile respecting the limit of three courses per year. Treatment
as regularly adapted so as to achieve the minimal effective dose
f local corticosteroids. Medication intake was recorded at each
onsultation, including intercurrent oral corticotherapy prescribed
y the patient’s community physician. Surgery was  performed
n case of persistent disabling symptoms despite 3 courses of
ral corticotherapy in the year, and consisted in radical endo-
copic ethmoidectomy under computer-assisted navigation and
eneral anesthesia. Medical treatment was systematically contin-
ed unchanged after surgery.CVID 0 1
Total 4 19
2.3. Statistical analysis
Statistical analysis screened for signiﬁcant correlation between
hormonal deﬁciency and age, gender, history of sinus surgery,
asthma, aspirin and NSAI intolerance, allergy (Table 1), rhinologic
symptoms, endoscopy score and local and general corticosteroid
doses. Chi2 tests were used for qualitative variables, or Fisher tests
for expected numbers less than 5. Ordinal qualitative variables
were assessed on Kruskal–Wallis test for independent variables or
Wilcoxon signed rank test for matched variables. The Welcha test
was used for quantitative variables. Kaplan–Meier actuarial anal-
ysis was  used to study symptom evolution according to humoral
status. Comparisons were made on log rank test. The signiﬁcance
threshold was  set at P < 0.05 for 2-tailed tests.
3. Results
Immunoglobulin subclass deﬁciency was detected in 13.7% of
cases (23 patients out of 161): 4 or 9.3% of patients managed med-
ically and 19 or 16.1% of patients managed surgically. Table 1
shows patient characteristics. IgG1 was the most frequent deﬁ-
ciency (47.8% of deﬁciencies) (Table 2). No correlation was  found
between Ig subclass deﬁciency and surgery: deﬁciency was  not
more frequent in patients managed surgically (P = 0.40), and there
was no signiﬁcant difference in the number of patients undergoing
iterative surgery with and without deﬁciency (P = 0.37). Prevalence
of asthma, aspirin or NSAI intolerance or allergy did not differ with
Ig subclass deﬁciency.With deﬁciency 21 16 18 5 11 21
P  1 0.913 0.878 0.085 0.650 0.658
NO: nasal obstruction; AR: anterior rhinorrhea; PR: posterior rhinorrhea; Snz:
sneezing; FP: facial pain; OD: olfactory disorder.
N. Tran Khai Hoan et al. / European Annals of Otorhinolaryn
Fig. 1. Top. Mean global symptom score at inclusion and on follow-up after
medical–surgical treatment in the deﬁcient and non-deﬁcient groups. Bottom. Num-
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dation from immunology experts. The methodological difﬁcultieser  of oral corticosteroid courses per year at inclusion and on follow-up in the 2
roups. There was no signiﬁcant inter-group difference.
everity, it did not otherwise signiﬁcantly differ between the 2
roups, nor did mean global clinical score (6.7 ± 2.3 vs 6.9 ± 2.4;
 = 0.82). There was no signiﬁcant difference in the distribution
f nasal polyposis grades. The one signiﬁcant difference was the
igher mean Lund–Mackay CT score in patients with than without
eﬁciency (20.7 ± 3.9 vs 17.6 ± 5.6, respectively; P = 0.002).
By 6 months post-surgery, global symptom score had fallen sig-
iﬁcantly (P < 0.001) in both groups, and did not differ between
roups over 5 years’ follow-up (Fig. 1). The distribution of polyposis
rades after treatment was identical in the 2 groups, i.e., following
urgery, there was no signiﬁcant difference according to Ig subclass
eﬁciency in symptom score or polyposis grade.
The most frequent symptoms were olfactory disorder, nasal
bstruction and posterior rhinorrhea. Actuarial symptom control
as assessed according to whether initial symptoms caused little
other (symptom grade 1) or impaired QoL (grade 2). Actuarial con-
rol of hyposmia at 3 and 5 years was respectively 36.4% and 25.3%
n the non-deﬁcient and 39.9% and 34.2% in the deﬁcient group
P = 0.46; Fig. 2A); for anosmia, respectively 80.6% and 71.6% versus
9.9% and 71.9% (P = 0.74; Fig. 2A); for nasal obstruction, respec-
ively 77.4% and 60.2% versus 78.5% and 62.4% (P = 0.67; Fig. 2B);
or severe nasal obstruction, respectively 94.1% and 89.8% versus
2.9% and 84.4% (P = 0.77; Fig. 2B); for posterior rhinorrhea, respec-
ively 66.1% and 52.5% versus 68.0% and 54.4% (P = 0.87; Fig. 2C);
nd for severe posterior rhinorrhea, respectively 92.1% and 79.2%
ersus 90.2% and 79.8% (P = 0.75; Fig. 2C), i.e., there was  no signif-
cant inter-group difference in control of olfactory disorder, nasal
bstruction or posterior rhinorrhea.
The number of oral corticosteroid courses needed to bring poly-
osis symptoms under control was signiﬁcantly lower 6 months
fter initiation of medical–surgical treatment in both groups
P < 0.001), but did not change between 6 months and 5 years in
ither group (P = 0.36 for non-deﬁcient and P = 0.51 for deﬁcient
atients). Oral corticosteroid dose was comparable between groups
hroughout follow-up (Fig. 1). Local corticosteroid dose fell signif-
cantly between 6 months and 5 years post-surgery (P = 0.005 for
on-deﬁcient and P = 0.003 for deﬁcient patients), but was  compa-
able between groups throughout follow-up.gology, Head and Neck diseases 131 (2014) 171–175 173
4. Discussion
Twenty-two of the 161 patients showed IgG subclass deﬁciency
(prevalence, 13.7%) and 1 presented CVID. The deﬁcient group com-
prised 11 IgG1, 1 IgG2, 6 IgG3, 4 associated IgG1 + IgG3 deﬁciencies
and 1 CVID. The literature reports IgG subclass deﬁciency preva-
lence ranging from 7% to 57% in patients with chronic ENT or
pulmonary infection, the most frequent deﬁciency being in IgG3
[8,9]. There is, however, no report of IgG subclass deﬁciency preva-
lence in the general population, without which it is not possible
to say whether the present ﬁnding of 13.7% is normal or elevated
[10]. We  therefore investigated the possible involvement of IgG
subclass deﬁciency in nasal polyposis severity by studying symp-
tom frequency and severity, endoscopic polyposis scores and local
and systemic treatments before and during the 5 years following
surgery.
Symptom frequency and severity and global symptom scores
were comparable between the IgG subclass deﬁcient and non-
deﬁcient groups at inclusion and throughout follow-up. Local
corticosteroid dose did not signiﬁcantly differ between groups, and
the same number of oral corticosteroid courses was  prescribed in
both, indicating a comparable number of exacerbation episodes.
Surgery, reserved to severe forms, was  not more frequent in deﬁ-
cient patients. The one severity criterion showing a signiﬁcant
inter-group difference was  the Lund–Mackay CT score, the clinical
interest of which, however, is relatively slight. There was  thus no
link between IgG subclass deﬁciency and nasal polyposis severity.
The link between humoral deﬁciency and nasal polyposis has
only rarely been a focus of study. Only 28 papers on immune dis-
order in chronic rhinosinusitis with or without polyps were found
among the 2378 articles retrieved from PubMed® using the key-
words “Sinusitis” and “Immune System Disease”. The other articles
concerned onset of ENT infection in immune deﬁciency without
polyposis. A single Thai study, presenting a few cases and a litera-
ture review, focused on nasal polyposis and IgG subclass deﬁciency
[11]. Four articles dealt with immune deﬁciency in chronic rhinos-
inusitis with or without polyps [12–15]; the other articles did not
mention nasal polyposis. Reported prevalence for humoral immune
deﬁciency in refractory rhinosinusitis varied between 5% and 63% of
patients, with considerable variation in speciﬁc deﬁciencies, such as
IgA deﬁciency, CVID and IgG subclass deﬁciency. These studies did
not distinguish between rhinosinusitis with and without polyps,
and IgG subclass deﬁciency was not conﬁrmed clinically.
IgG subclass deﬁciency is diagnosed from the association of
strict biological and clinical criteria. Twenty-ﬁve years after the
ﬁrst descriptions, controversy persists as to the biological signif-
icance of isolated IgG subclass deﬁciency. On the one hand, partial
or total deﬁciency in one or more IgG subclasses is not neces-
sarily associated with marked susceptibility to infection, while
on the other hand, certain serological responses may  be insufﬁ-
cient in some patients with normal IgG subclass levels [8,10,16].
Subclass deﬁciency is nevertheless an altogether recognized patho-
logical entity, and diagnosis should not be founded on IgG subclass
assay alone but should take account of clinical status, the clinical
alarm signals being iterative ENT infection, severe bacterial infec-
tion and bronchiectasis. Another diagnostic pitfall concerns IgG
subclass assay: the prevalence of subclass deﬁciency in patients
with recurrent infection varies greatly from study to study (5%
to 60%) [10,17–18], reﬂecting not only sample heterogeneity but
also diversity of IgG subclass measurement methods and varia-
tions in IgG subclass rates. Numerous IgG subclass assay methods
have been developed, none of which has received clear recommen-relate to the nature of IgGs: subclasses differ only in a limited num-
ber of speciﬁc epitopes (great homology), while a large number of
individual factors of heterogeneity (allo- and idio-typic markers)
174 N. Tran Khai Hoan et al. / European Annals of Otorhinolaryngology, Head and Neck diseases 131 (2014) 171–175
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Fig. 2. Control of olfaction disorder (top, A), nasal obstruction (middle, B) and posterior rhinorrhea (bottom, C) in patients without ( ) and with (—) humoral immunodeﬁciency.
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p-axis:  (top, A) % without hyposmia (left) and anosmia (right); (middle, B) % without n
hinorrhea (left) and severe posterior rhinorrhea (right). Arbitrarily, the percentage o
nter-group differences.
ay  bias assay [19]. Assays should therefore speciﬁcally measure
ach IgG isotype, without being affected by individual factors. There
s a certain degree of correlation between techniques, but refer-
nce values vary according to the method and type of antibodies
sed; this may  account for the variations in reported deﬁciency
revalence.bstruction (left) and severe nasal obstruction (right); (bottom, C) % without posterior
nts without symptom is set at 100% for the day of surgery. There were no signiﬁcant
Biological conﬁrmation is needed following a ﬁrst positive
result, indicating IgG subclass deﬁciency: certain isotypes (IgG3)
are unstable and require fast transfer of the sample to avoid biasing
the assay. Moreover, subclass rates vary with age, ethnicity and his-
tory of infection. Transient secondary deﬁciencies, usually lasting a
few months or years, may  also follow radiation or chemo-therapy
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immunoglobulin allotypes on IgG subclass concentrations. J Periodont ResN. Tran Khai Hoan et al. / European Annals of Otorhin
or Hodgkin’s disease (IgG2 deﬁciency), bone-marrow graft (1 year
f IgG2-IgG4 deﬁciency), HIV infection (elevated IgG1 and IgG3
ith reduced IgG2 and IgG4 and functional antibody deﬁciency),
lcohol-related liver disease or digestive surgery. Likewise, high-
ose corticosteroids may  reduce IgG3 levels when greater than
0 mg/day prednisolone for 7 days, and IgG1 and IgG2 levels when
reater than 40 mg/day [16,20–22].
. Conclusion
This was the ﬁrst European study of the association between IgG
ubclass deﬁciency and nasal polyposis. It failed to demonstrate a
ink between the two, for lack of reference data on general popula-
ion prevalence. Over the 5 years of follow-up, the one signiﬁcant
ifference to emerge was the higher Lund–Mackay score in the
eﬁcient group; global symptom score, severity of hyposmia, nasal
bstruction and rhinorrhea and polyposis grade showed no signiﬁ-
ant deﬁciency-related differences. Although no conclusion can be
rawn as to an association between IgG subclass deﬁciency and
asal polyposis, deﬁciency would not seem to inﬂuence severity or
volution after medical–surgical treatment.
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